Wnt signaling in bone metastasis: mechanisms and therapeutic opportunities
Authors:
- 1 September 2018
- journal article
- review article
- Published by Elsevier in Life Sciences
- Vol. 208, 33-45
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81771065)
- West China Hospital of Stomatology (2016-3)
- Sichuan University (2018SCU12024)
- National Natural Science Foundation of China (81600859)
- Science Foundation of Sichuan Province (17-YCG053)
This publication has 160 references indexed in Scilit:
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Chemical-Genetic Screen Identifies Riluzole as an Enhancer of Wnt/β-catenin Signaling in MelanomaChemistry & Biology, 2010
- Integration of BMP and Wnt signaling via vertebrate Smad1/5/8 and Drosophila MadCytokine & Growth Factor Reviews, 2009
- mTOR Mediates Wnt-Induced Epidermal Stem Cell Exhaustion and AgingCell Stem Cell, 2009
- Sulindac Inhibits Canonical Wnt Signaling by Blocking the PDZ Domain of the Protein DishevelledAngewandte Chemie International Edition, 2009
- WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma MetastasisCell, 2009
- Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 TrialEuropean Urology, 2009
- Dickkopf‐1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasisThe Prostate, 2008
- Sulindac suppresses β-catenin expression in human cancer cellsEuropean Journal of Pharmacology, 2008
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889